Cargando…

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study

Psoriasis, a chronic inflammatory skin disease, negatively impacts patients’ quality of life (QoL). This randomized, phase III, double‐blind, placebo‐controlled, multicenter study evaluated the efficacy and safety of brodalumab, a human anti‐interleukin‐17 receptor A monoclonal antibody, in Korean p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Seong Jun, Shin, Bong Seok, Lee, Joo‐Heung, Jeong, Haeyoun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246806/ https://www.ncbi.nlm.nih.gov/pubmed/33373480 http://dx.doi.org/10.1111/1346-8138.15733

Ejemplares similares

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2023)

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
por: Coimbra, Susana, et al.
Publicado: (2014)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Paller, A.S., et al.
Publicado: (2020)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Protocol for the safety of brodalumab regarding psychiatric comorbidities in patients with psoriasis
por: Pikou, O., et al.
Publicado: (2022)

Which Areas Are Still Left in Biologics Responsive Korean Patients with Moderate to Severe Plaque Psoriasis
por: Won, Sang-Hyeon, et al.
Publicado: (2023)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022)

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
por: Cai, Lin, et al.
Publicado: (2021)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
por: Feldman, Steven R., et al.
Publicado: (2018)

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study
por: Cai, L., et al.
Publicado: (2016)

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
por: Wei, James Cheng-Chung, et al.
Publicado: (2021)

Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
por: Elgaard, Cathrine Dawn Büttner, et al.
Publicado: (2023)

The effect of Melissa officinalis syrup on patients with mild to moderate psoriasis: a randomized, double-blind placebo-controlled clinical trial
por: Yargholi, Alireza, et al.
Publicado: (2021)

Brodalumab, an anti–interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study
por: Kim, Tae-Hwan, et al.
Publicado: (2022)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
por: Kokolakis, Georgios, et al.
Publicado: (2021)

Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study
por: Ohata, Chika, et al.
Publicado: (2023)

Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sf6rs6h4tma6mvq8r26tsbjc2a